# Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study

> **NCT07085182** · PHASE2 · RECRUITING · sponsor: **Zibo Municipal Hospital** · enrollment: 20 (estimated)

## Conditions studied

- NSCLC
- Tislelizumab
- Chemotherapy
- Hypofractionated Radiotherapy

## Interventions

- **DRUG:** SBRT combined with Tislelizumab followed by Tislelizumab

## Key facts

- **NCT ID:** NCT07085182
- **Lead sponsor:** Zibo Municipal Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-13
- **Primary completion:** 2027-12-10
- **Final completion:** 2028-12-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07085182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07085182, "Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07085182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*